SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| CIMZIA 200 mg Solution for Injection | 200 mg | Solution for injection · Subcutaneous use | 2 Pre-filled syringe | SAR 2839.40 | Biological · Prescription | U.C.B. | Valid |
Indications — CHI Daman Drug Formulary
ANKYLOSING SPONDYLITIS; CROHN'S DISEASE; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARITHRITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| CIMZIA | 200MG | injectable · injection | UCB INC | Prescription | 22 Apr 2008 |
EMA European Union — centrally authorised medicines
Cimzia UCB Pharma · Authorised · authorised 1 Oct 2009 · ATC L04AB05
Therapeutic indication (EMA)
Rheumatoid arthritis Cimzia, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate the treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs. Cimzia has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function, when given in combination with MTX. Axial spondyloarthritis Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising: Ankylosing spondylitis (AS) Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Axial spondyloarthritis without radiographic evidence of AS Adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs. Psoriatic arthritis Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
Cimzia UCB Pharma SA · Refused · ATC L04AB05
Therapeutic indication (EMA)
Cimzia, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARD) including methotrexate, has been inadequate.Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| CIMZIA | 02331675 | 200 MG / ML | SOLUTION · SUBCUTANEOUS | UCB CANADA INC |
| CIMZIA | 02465574 | 200 MG / ML | SOLUTION · SUBCUTANEOUS | UCB CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | CIMZIA 2X200 MG/ML SYRINGE KIT | $6094.025 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 8.1. Immunomodulators for non-malignant disease · complementary
Therapeutic equivalent to adalimumab for Axial spondyloarthritis; Therapeutic equivalent to adalimumab for Crohn disease site; Therapeutic equivalent to adalimumab for Rheumatoid arthritis - 29.3. Medicines for juvenile joint diseases · complementary
Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis - 13.4. Dermatological medicines > Medicines affecting skin differentiation and proliferation · complementary
Therapeutic equivalent to adalimumab for Psoriasis of unspecified type
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.